4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)

BOULDER, Colo., June 17, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that it has filed an Answer (the "Answer") to a Verified Petition for Appointment of a Custodian Pursuant to 8 Del. C. § 226 (the "Delaware Petition") that was filed with the Court of Chancery of the State of Delaware (the "Court") on May 17, 2024 by a stockholder and former General Counsel, Chief Compliance Officer, and Secretary of the Company, David R. McAvoy (the "Petitioner"). The Delaware Petition, to which the Answer outlines the Company is in overall agreement with, specifically requests that the Court issue an order appointing Albert N. Ma

BOULDER, Colo., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. ("Fresh Tracks" or the "Company") (NASDAQ:FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced its Board of Directors has appointed Andrew Sklawer, the Company's current President, as Chief Executive Officer (CEO), effective February 1, 2023. Mr. Sklawer will succeed Rob Brown, who has led the company as CEO since 2019 and is retiring. Mr. Brown will continue to serve as a non-executive member of the Board

BOULDER, Colo., June 17, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that it has filed an Answer (the "Answer") to a Verified Petition for Appointment of a Custodian Pursuant to 8 Del. C. § 226 (the "Delaware Petition") that was filed with the Court of Chancery of the State of Delaware (the "Court") on May 17, 2024 by a stockholder and former General Counsel, Chief Compliance Officer, and Secretary of the Company, David R. McAvoy (the "Petitioner"). The Delaware Petition, to which the Answer outlines the Company is in overall agreement with, specifically requests that the Court issue an order appointing Albert N. Ma

Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") would like to remind its stockholders to vote their proxy ahead of the Company's upcoming special meeting of stockholders on February 15, 2024 (the "Special Meeting") at 12:00 p.m. Eastern Time to seek stockholder approval of the liquidation and dissolution of the Company (the "Dissolution") and the plan of liquidation and dissolution (the "Plan of Dissolution"). All stockholders of record of the Company's outstanding shares of

New record date expected to be January 11, 2024 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders at new special meeting, which would reduce the amount of cash distributable to stockholders BOULDER, Colo., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) ("Fresh Tracks" or the "Company") announced today plans to hold a new special meeting of stockholders on February 15, 2024 (the "Special Meeting") to seek stockholder approval of the liquidation and dissolution of the Company (the "Dissolution") and the plan of liquidation and dissolution (the "Plan of Dissolution"). As of today's r

BOULDER, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that the Company's common stock was suspended from trading on The Nasdaq Capital Market at the open of business. Following the suspension, the Company's common stock now is quoted on the OTC Pink market under the same trading symbol, "FRTX." The Company has withdrawn its appeal of Nasdaq's determination to delist the Company's common stock, which will no longer trade on The Nasdaq Capital Market. Fresh Tracks intends to reconvene its special meeting of stockholders on December 27, 2023 and encourages all stockholders of record on October 17, 2023 w

BOULDER, Colo., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) ("Fresh Tracks" or the "Company") announced today receipt of a notice from Nasdaq stating that the Company's common stock will be suspended from trading on The Nasdaq Capital Market at the open of business on December 19, 2023. Following the suspension, the Company expects its common stock to begin trading on an over-the-counter market. The Company anticipates disclosing further trading market information for its common stock once such information becomes available. As previously disclosed, on October 10, 2023, the Company received a notice from the Listing Qualifications Department (the "Staff

Meeting adjourned to December 27, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m. Eastern Time on December 26, 2023 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders, which would reduce the amount of cash distributable to the stockholders BOULDER, Colo., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) ("Fresh Tracks" or the "Company") announced today that its special meeting of stockholders (the "Special Meeting"), which was previously adjourned on November 16, 2023 and November 30, 2023, has b

Meeting adjourned to December 15, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m. Eastern Time on December 14, 2023 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders, which would reduce the amount of cash distributable to the stockholders BOULDER, Colo., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) ("Fresh Tracks" or the "Company") announced today that its special meeting of stockholders (the "Special Meeting"), which was previously adjourned on November 16, 2023, has been adjourned for a se

Meeting adjourned to November 30, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m. Eastern Time on November 29, 2023 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders, which would reduce the amount of cash distributable to the stockholders BOULDER, Colo., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) ("Fresh Tracks" or the "Company") announced today that its special meeting of stockholders (the "Special Meeting") has been adjourned to Thursday, November 30, 2023 at 10 a.m. Mo

Cash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution If approved by stockholders, the Company estimates that cash distributions in the Dissolution will be between $5 million and $7 million, or $0.84 to $1.17 per share, to stockholders BOULDER, Colo., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. "Following the approval by our Board of a plan of liquidation and di

BOULDER, Colo., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX) today announced that, after conducting an extensive potential strategic alternatives process and careful consideration of the outcomes of this, its Board of Directors has approved a plan of liquidation and dissolution of the Company (the "Plan of Dissolution"). In connection with the liquidation and dissolution of the Company, which is subject to shareholder approval, the Company intends to distribute all remaining cash to shareholders. Additionally, in order to reduce costs, Fresh Tracks is discontinuing all clinical and preclinical development programs, and r

The Dow Jones index closed higher by around 575 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Grove Collaborative Holdings The Trade: Grove Collaborative Holdings, Inc. (NYSE:GROV) President and CEO Jeffrey Michael Yurcisin bought a total of 17,100 shares at an average price of $1.63. To acquire these shares, it cost around $27,951. Wh

The Dow Jones index closed lower by 0.5% on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. MultiPlan The Trade: MultiPlan Corporation (NYSE:MPLN) Director Anthony Colaluca Jr bought a total of 160,000 shares at an average price of $0.60. To acquire these shares, it cost around $96,000. What's Happening: On May 8, MultiPlan posted a GAAP loss of

The Dow Jones index closed higher by more than 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. TSS The Trade: TSS, Inc. (OTC:TSSI) President and CEO Darryll E Dewan acquired a total of 10,000 shares an average price of $0.60. To acquire these shares, it cost around $6,000.. What’s Happening: On March 28, TSS, reported results for its

The Dow Jones index closed higher by over 250 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Vista Gold The Trade: Vista Gold Corp. (NYSE:VGZ) CFO Douglas L. Tobler acquired a total of 3,500 shares an average price of $0.48. To acquire these shares, it cost around $1,691. What’s Happening: On March 14, Vista Gold posted a fourth-quarte

The Dow Jones index closed higher by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Rave Restaurant The Trade: Rave Restaurant Group, Inc. (NASDAQ:RAVE) CEO Brandon Solano acquired a total of 11,376 shares an average price of $1.72. To acquire these shares, it cost around $19,621. What’s Happening: On Feb. 1, RAVE Restaurant Grou

The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. OPKO Health The Trade: OPKO Health, Inc. (NASDAQ:OPK) 10% owner Frost Gamma Investments Trust acquired a total of 500,000 shares an average price of $0.99. To acquire these shares, it cost around $496,150. What’s Happening: On Feb. 27, OPKO Hea

The Dow Jones index closed slightly higher on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Entera Bio The Trade: Entera Bio Ltd. (NASDAQ:ENTX) Director Haya Taitel acquired a total of 7,615 shares an average price of $0.77. To acquire these shares, it cost around $5,86. What’s Happening: Entera Bio announced that it received an extension of 18

Fresh Tracks Therapeutics Inc (NASDAQ:FRTX) shares are volatile Monday morning, trading higher by 3.2% to $0.84, after the company received a notice from Nasdaq stating its common stock will be suspended from trading on Nasdaq and is expected to move to an over-the-counter market. This action followed the company's decision to withdraw an appeal and seek delisting from Nasdaq in preparation for a planned liquidation and dissolution. Fresh Tracks says they've scheduled a stockholders' meeting to vote on the approval of the liquidation plan; the company says failure to approve it might lead to a judicial dissolution, which could be costly and reduce the cash distribution to stockholders duri

Fresh Tracks intends to reconvene its special meeting of stockholders on December 27, 2023 and encourages all stockholders of record on October 17, 2023 who have not yet voted to submit their proxy by 11:59 p.m. Eastern Time on December 26, 2023. If Fresh Tracks' stockholders do not approve Proposal 1, Approval of the Liquidation and Dissolution of the Company and the Plan of Liquidation and Dissolution (the "Plan of Dissolution"), which, if approved, will authorize the Company and the Board of Directors to Liquidate and Dissolve the Company in accordance with the Plan of Dissolution, Fresh Tracks intends to seek judicial dissolution, which is likely to be costly and time-consuming and would

Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023 Ongoing evaluation of strategic options to further develop FRTX-02 and maximize shareholder value Strengthened balance sheet with aggregate net proceeds of $6.6 million raised under an ATM program in March 2023 BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today

Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases Continuing to evaluate strategic options to further develop FRTX-02 and maximize shareholder value Raised aggregate net proceeds of $6.6 million under ATM program in March 2023 BOULDER, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription the

SC 13D - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)

15-12G - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

10-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

DEFA14A - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

DEF 14A - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

PRE 14A - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

S-8 POS - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)

S-8 POS - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)